Eli Lilly and Company (NYSE: LLY) announced today the U.S. Food and Drug Administration (FDA) approved EBGLYSS™ (lebrikizumab-lbkz), a targeted IL-13 inhibitor, for the treatment of adults and ...

Eli Lilly is still celebrating the FDA approval of its amyloid-directed Alzheimer's therapy Kisunla but has had less fortune with a candidate against tau, another well-established drug target for ...

FDA approves Lilly's eczema drug, Ebglyss, and the expanded use of Novartis' Kisqali, Merck's Keytruda and AstraZeneca's Fasenra. Novo Nordisk’s American depositary receipts tumbled almost 6% ...

Eli Lilly's latest clinical readout for dual GIP/GLP-1 agonist tirzepatide is a big one, with data suggesting the drug can reduce the risk of developing type 2 diabetes in overweight and obese ...

This advertisement has not loaded yet, but your article continues below. He sees conservative ideas as more than a ticket to power Higgs drew the party's ire during remarks made at his Thursday ...

Instead of an app or gadget that claims to jump-start your productivity, consider investing in a good paper planner. There is plenty of research that shows how actually writing down your to-do ...

Agenda 21 is a comprehensive plan of action to be taken globally, nationally and locally by organizations of the United Nations System, Governments, and Major Groups in every area in which human ...

Steve Paikin is the host of TVO's flagship current affairs program, The Agenda with Steve Paikin. He co-hosts the weekly provincial affairs #onpoli podcast and contributes columns to tvo.org. Paikin ...